Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of AD-230 in Healthy Adults
NCT07521241Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- May 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + amlodipine + chlorthalidone in chronic liver disease (CLD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Planned start May 2026; status: not yet recruiting.
02
Drugs
telmisartan + amlodipine + chlorthalidone
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT07521241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521241.